A6X Stock Chart & Stats
€0.21
<€0.01(1.32%)
At close: 4:00 PM EST
€0.21
<€0.01(1.32%)
Day’s Range― - ―
52-Week Range€0.07 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€15.93M
Enterprise Value€83.71M
Total Cash (Recent Filing)€4.00M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding67,729,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.33
Price to Sales (P/S)6.68
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€3.53M
Bulls Say, Bears Say
Bulls Say
Proprietary Phenylcapsaicin PlatformOwning a focused, proprietary active ingredient (phenylcapsaicin) creates a durable competitive asset for specialty-chemical applications. This supports product differentiation, potential licensing, and long-term revenue streams if regulatory approvals and commercial adoption in feed and other markets scale.
Low Financial Leverage And Meaningful EquityA debt-free balance sheet with substantial equity reduces refinancing risk and gives management optionality to fund commercialization, R&D, or partnerships. This structural strength supports resilience through cash burn periods and enables strategic investments without near-term solvency pressure.
Revenue Scale Improving And Gross Margin RecoveryRising revenues and a rebound to positive gross margin indicate early operational traction and improved unit economics. If sustained, this trend supports a pathway to profitability as fixed costs are leveraged and commercial adoption of the active ingredient expands across feed and adjacent applications.
Bears Say
Persistent Negative Operating And Free Cash FlowOngoing cash burn means the company cannot self-fund growth from operations and will need external financing or equity dilution to continue commercialization efforts. Over multiple quarters this weakens financial flexibility and raises execution risk for scaling the business.
Deeply Negative Operating And Net MarginsLarge negative EBIT and net margins show current operations do not cover operating costs. Structural profitability gaps require either substantial revenue scale, sustained margin expansion, or cost base reduction; absent these, equity value and reinvestment capacity erode over time.
Unclear Commercialization Partnerships And Revenue DiversificationRevenue reliance on selling an ingredient without disclosed major partners or licensing agreements increases execution risk. Lack of visible, contractual commercial anchors makes future revenue growth dependent on securing partners and scaling distribution, which can be time-consuming and capital intensive.
aXichem AB Class A News
A6X FAQ
What was aXichem AB Class A’s price range in the past 12 months?
aXichem AB Class A lowest stock price was €0.07 and its highest was €0.32 in the past 12 months.
What is aXichem AB Class A’s market cap?
aXichem AB Class A’s market cap is €15.93M.
When is aXichem AB Class A’s upcoming earnings report date?
aXichem AB Class A’s upcoming earnings report date is Aug 27, 2026 which is in 34 days.
How were aXichem AB Class A’s earnings last quarter?
aXichem AB Class A released its earnings results on May 21, 2026. The company reported -€0.012 earnings per share for the quarter, the consensus estimate of -€0.012 by €0.
Is aXichem AB Class A overvalued?
According to Wall Street analysts aXichem AB Class A’s price is currently Overvalued.
Does aXichem AB Class A pay dividends?
aXichem AB Class A does not currently pay dividends.
What is aXichem AB Class A’s EPS estimate?
aXichem AB Class A’s EPS estimate is -0.01.
How many shares outstanding does aXichem AB Class A have?
aXichem AB Class A has 67,729,120 shares outstanding.
What happened to aXichem AB Class A’s price movement after its last earnings report?
aXichem AB Class A reported an EPS of -€0.012 in its last earnings report, expectations of -€0.012. Following the earnings report the stock price went up 4.301%.
Which hedge fund is a major shareholder of aXichem AB Class A?
Currently, no hedge funds are holding shares in DE:A6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
aXichem AB Class A
aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.
Technical Analysis
Nexam Chemical Holding AB
―
―
Svenska Aerogel Holding AB
―
OrganoClick AB
―
XP Chemistries AB
―